Changes in aqueous concentrations of various cytokines after intravitreal bevacizumab and subtenon triamcinolone injection for diabetic macular edema

Macular Diseases

Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema

Hillier RJ, Ojaimi E, Wong DT,

Macular Diseases

Anatomic Response to Intravitreal Dexamethasone Implant and Baseline Aqueous Humor Cytokine Levels in Diabetic Macular Edema

Invest Ophthalmol Vis Sci.

Figueras-Roca M, Sala-Puigdollers A, Zarranz-Ventura J, Alba-Linero C, Alforja S, Esquinas C, Molins B, Adán A

doi: 10.1167/iovs.

COMMENTED

Macular Diseases

Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial

JAMA Ophthalmol.

Bressler NM, Odia I, Maguire M, Glassman AR, Jampol LM, MacCumber MW, Shah C, Rosberger D, Sun JK, DRCR Retina Network.

doi: 10.1001/jamaophthalmol.

Macular Diseases

Retinal vascular calibre changes after intravitreal bevacizumab or dexamethasone implant treatment for diabetic macular oedema

Br J Ophthalmol.

Wickremasinghe SS, Fraser-Bell S, Alessandrello E, Mehta H, Gillies MC, Lim LL

doi: 10.1136/bjophthalmol-

Macular Diseases

Aqueous Humor Cytokines and Long-Term Response to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema

Am J Ophthalmol.

Felfeli T, Juncal VR, Hillier RJ, Mak MY, Wong DT, Berger AR, Kohly RP, Kertes PJ, Eng K, Boyd SR, Altomare F, Giavedoni LR, Muni RH

doi: 10.1016/j.ajo.

Macular Diseases

Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial

JAMA Ophthalmol.

Bressler NM, Beaulieu WT, Glassman AR, Blinder KJ, Bressler SB, Jampol LM, Melia M, Wells JA 3rd; Diabetic Retinopathy Clinical Research Network

doi: 10.1001/

Macular DiseasesSurgery and Intervention

CHANGES OF AQUEOUS HUMOR MÜLLER CELLS' BIOMARKERS IN HUMAN PATIENTS AFFECTED BY DIABETIC MACULAR EDEMA AFTER SUBTHRESHOLD MICROPULSE LASER TREATMENT

Retina.

Midena E, Bini S, Martini F, Enrica C, Pilotto E, Micera A, Esposito G, Vujosevic S

doi: 10.1097/IAE.

Macular Diseases

Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success

Graefes Arch Clin Exp Ophthalmol.

Laiginhas R, Silva MI, Rosas V, Penas S, Fernandes VA, Rocha-Sousa A, Carneiro Â, Falcão-Reis F, Falcão MS

doi: 10.1007/s00417-017-3836-1.

COMMENTED

Macular Diseases

Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial

JAMA Ophthalmol.

Hykin P, Prevost AT, Vasconcelos JC, Murphy C, Kelly J, Ramu J, Hounsome B, Yang Y, Harding SP, Lotery A, Chakravarthy U, Sivaprasad S, LEAVO Study Group.

doi: 10.1001/

Related content

Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema

Anatomic Response to Intravitreal Dexamethasone Implant and Baseline Aqueous Humor Cytokine Levels in Diabetic Macular Edema

Association Between Change in Visual Acuity and Change in Central Subfield Thickness During Treatment of Diabetic Macular Edema in Participants Randomized to Aflibercept, Bevacizumab, or Ranibizumab: A Post Hoc Analysis of the Protocol T Randomized Clinical Trial

Retinal vascular calibre changes after intravitreal bevacizumab or dexamethasone implant treatment for diabetic macular oedema

Aqueous Humor Cytokines and Long-Term Response to Anti-Vascular Endothelial Growth Factor Therapy in Diabetic Macular Edema

Persistent Macular Thickening Following Intravitreous Aflibercept, Bevacizumab, or Ranibizumab for Central-Involved Diabetic Macular Edema With Vision Impairment: A Secondary Analysis of a Randomized Clinical Trial

CHANGES OF AQUEOUS HUMOR MÜLLER CELLS' BIOMARKERS IN HUMAN PATIENTS AFFECTED BY DIABETIC MACULAR EDEMA AFTER SUBTHRESHOLD MICROPULSE LASER TREATMENT

Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success

Clinical Effectiveness of Intravitreal Therapy With Ranibizumab vs Aflibercept vs Bevacizumab for Macular Edema Secondary to Central Retinal Vein Occlusion: A Randomized Clinical Trial